Drug intelligence / Profile preview

CCT-117

Development stage: Preclinical
Lead developer: Canary Global
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

CCT-117 is an investigational small interfering RNA (siRNA) therapeutic developed by Canary (Canary Cure) for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The drug is part of Canary's pipeline of RNAi-based therapies generated through its 'Reprogram Platform,' which utilizes human genetic data and AI to identify targets for metabolic disease. CCT-117 specifically targets pathways involved in satiety regulation and energy balance, aiming to provide a long-acting treatment option via subcutaneous injection. As of 2024, CCT-117 is in the IND-enabling phase of development, following the company's lead program, CCT-217.

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on CCT-117.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CCT-117.

Explore the full profile